Inogen beats Q2 estimates, but shares still drop
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Procore reports growing revenue and shrinking losses, but narrowly misses analysts’ Q2 estimates
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Montecito Bank & Trust assets approach $2.5B
Montecito Bank & Trust, the biggest bank based in the tri-county region, reported total assets increased nearly 13% during the 12 months ending June 30. The Santa Barbara-based bank saw total assets grow $276.45 million during the period, closing at $2.46 billion, it said in a quarterly report released Aug. 5. Montecito Bank & Trust Read More →
Amgen beats analysts’ expectations for earnings and revenue in Q2
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Velocity reports earnings growth in Q2
Real estate finance company Velocity Financial saw its second quarter net income increase and its total loan portfolio grow from 2021 to 2022, according to an earnings statement the company released on Aug. 4. The Westlake Village-based company reported net income of $10.6 million, or diluted earnings per share of 31 cents, in the second Read More →
Amgen to buy ChemoCentryx for $3.7B
Amgen was having a relatively quiet year on the mergers and acquisitions front, at least until Aug. 4, when the Thousand Oaks-based biotech firm announced it will purchase ChemoCentryx for nearly $3.7 billion. ChemoCentryx is a Silicon Valley biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has Read More →
Arcutis to raise $150M in public stock offering
Arcutis Biotherapeutics, a Westlake Village-based company developing drugs for immune dermatological conditions, plans to raise $150 million through a public offering of additional shares of common stock. Arcutis announced the pricing of those shares on Aug. 2, at $20 per share. Shares of Arcutis closed at $19.50 that day and then shot up 17% on Read More →
